Twin Focus Capital Partners LLC purchased a new stake in Quanterix Corp (NASDAQ:QTRX) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 10,000 shares of the company’s stock, valued at approximately $258,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of QTRX. New York State Common Retirement Fund grew its stake in Quanterix by 116.7% during the 4th quarter. New York State Common Retirement Fund now owns 6,500 shares of the company’s stock worth $119,000 after buying an additional 3,500 shares during the last quarter. Alambic Investment Management L.P. acquired a new position in shares of Quanterix in the 1st quarter valued at about $353,000. Vanguard Group Inc. lifted its holdings in shares of Quanterix by 194.4% in the 3rd quarter. Vanguard Group Inc. now owns 345,281 shares of the company’s stock valued at $7,396,000 after buying an additional 227,999 shares during the period. Granite Investment Partners LLC lifted its holdings in shares of Quanterix by 51.0% in the 4th quarter. Granite Investment Partners LLC now owns 24,426 shares of the company’s stock valued at $448,000 after buying an additional 8,248 shares during the period. Finally, Jennison Associates LLC raised its holdings in Quanterix by 1.1% in the 4th quarter. Jennison Associates LLC now owns 297,563 shares of the company’s stock worth $5,448,000 after purchasing an additional 3,249 shares during the period. 51.61% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ QTRX traded down $0.58 during mid-day trading on Friday, hitting $33.48. The company had a trading volume of 120,413 shares, compared to its average volume of 264,069. The company has a current ratio of 3.10, a quick ratio of 2.64 and a debt-to-equity ratio of 0.22. Quanterix Corp has a 1-year low of $13.00 and a 1-year high of $34.32.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.17). Quanterix had a negative net margin of 79.48% and a negative return on equity of 76.62%. The business had revenue of $10.88 million during the quarter, compared to analyst estimates of $9.69 million. On average, research analysts forecast that Quanterix Corp will post -1.56 earnings per share for the current fiscal year.

In other Quanterix news, Chairman E Kevin Hrusovsky sold 2,142 shares of Quanterix stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $22.59, for a total value of $48,387.78. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP David C. Duffy sold 1,277 shares of Quanterix stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $20.78, for a total value of $26,536.06. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,862 shares of company stock worth $351,252. Corporate insiders own 30.80% of the company’s stock.

A number of equities analysts have commented on the company. Canaccord Genuity reissued a “buy” rating and set a $29.00 target price on shares of Quanterix in a report on Friday, March 8th. Zacks Investment Research upgraded Quanterix from a “sell” rating to a “hold” rating in a research report on Thursday, May 9th.

TRADEMARK VIOLATION NOTICE: “Twin Focus Capital Partners LLC Purchases New Stake in Quanterix Corp (NASDAQ:QTRX)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2019/06/16/twin-focus-capital-partners-llc-purchases-new-stake-in-quanterix-corp-nasdaqqtrx.html.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

Further Reading: How is the discount rate different from the Federal Funds rate?

Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Corp (NASDAQ:QTRX).

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.